Evotec announces CEO transition

Dr. Werner Lanthaler steps down as CEO

Evotec SE announced that after close to 15 years of successful service, CEO Dr Werner Lanthaler has informed the company, that he will not continue to serve until the end of his current term (March 2026), for personal reasons. The Supervisory Board has accepted his resignation from his office.

Evotec has started the search for a permanent solution for the position of CEO.

Werner Lanthaler will support a smooth and prompt transition of ongoing projects in the coming weeks. He will continue to be available as a strategic advisor to the company’s Supervisory Board, especially in the company’s activities for better access to medicines in Africa and less developed countries in Asia.

The Supervisory Board has started an internal and external search for a permanent CEO. In the meantime, Dr Mario Polywka, currently Supervisory Board member and former COO of Evotec, agreed to serve as interim CEO.

The company sees itself on a strong path, especially based on its paradigm-shifting technologies, such as PanOmics, iPSC and Just – Evotec Biologics. This constitutes one of the strongest drug discovery and development platforms in the industry.

Evotec confirms its company guidance 2023, as communicated in the 9M 2023 results publication on 8 November 2023. 

Dr Werner Lanthaler, commented: “After an extremely challenging, and also physically and overall, very exhausting 2023, and upon deep reflection in the last weeks and into the new year, I came to the conclusion to step down as CEO, as I could not serve the company to the best of my ability in the coming years. The company is in a very strong position, and the teams are delivering excellent work, so that the execution of our long-term strategy is secured and well on track. With PanOmics driven drug-discovery, iPSCs, and Just – Evotec Biologics the company is set up for long-term global leadership and success.

I want to thank all my co-workers, friends, partners, investors, my Management teams and Supervisory Board for a wonderful and most inspirational time. Building THE leading company for external innovation globally is just at the beginning, and I feel that we all made a great start together. Before starting my next entrepreneurial chapter, I intend to take an educational sabbatical over the next six to nine months, focused on disruptive themes in technology and political changes.”

Prof. Dr Iris Löw-Friedrich, Chairperson of Evotec’s Supervisory Board, stated: “On behalf of the members of the Supervisory Board and everyone at Evotec, I would like to express my sincere gratitude to Werner for his unique vision and many important achievements over the course of the last almost 15 years. Together with the deeply committed and highly competent teams in Evotec, he formed a most respected innovation platform for the discovery and development of new medicines. Werner joined Evotec at a time when the company was in a very difficult situation and has shaped a business model, which is now unique in the industry. We respect his decision, we stay in contact, and wish him all the best for his future.”

More News

Hamburg's Senator for Economics and Innovation, Dr. Melanie Leonhard, met Dr. Werner Lanthaler, Evotec CEO (left), and Dirk Winkler, SVP Hit Identification, Global Drug Discovery Services at Evotec (right), during her visit to the Manfred Eigen campus.
Hamburg's Senator for Economics and Innovation, Dr. Melanie Leonhard, met Dr. Werner Lanthaler, Evotec CEO (left), and Dirk Winkler, SVP Hit Identification, Global Drug Discovery Services at Evotec (right), during her visit to the Manfred Eigen campus. ( Picture: © Nico Michaelsen, Evotec SE)

Senator Dr. Melanie Leonhard visits Evotec

Evotec SE announced that new high-throughput screening (“HTS”) facilities at the Company’s headquarters in Hamburg, as well as additional equipment for investigating ...

Read more …
For academic research, MHH will receive access to the data generated within the partnership by working with Evotec’s AI-driven analytics software PanHunter. (Picture: © Evotec)

Evotec enters partnership with Hannover Medical School

Evotec SE announced that the Company has entered a partnership with Hannover Medical School (“MHH”), one of the leading German universities, to ...

Read more …
Preview of the new biologics manufacturing plant J.POD® Toulouse, France (EU); (Image: © Brunerie & Irissou Architectes, Thomas Brunerie)

Evotec initiates ground-breaking for new biologics facility

Evotec SE today officially launched the construction of its J.POD® biologics manufacturing facility at Evotec’s Campus Curie in Toulouse, France. J.POD® Toulouse, ...

Read more …